Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 15/20 | 0.70 |
| ▸ | CLK2 | P49760 | 14/20 | 0.70 |
| ▸ | CLK3 | P49761 | 14/20 | 0.70 |
| ▸ | WNT1 | P04628 | 5/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17583417 | 0.92 | DYRK1A (0.75) | DYRK1ACLK2CLK3WNT1GSK3B | |
| SCHEMBL17568276 | 0.90 | CLK2 (0.83) | DYRK1ACLK2CLK3WNT1PIM1 | |
| SCHEMBL17569683 | 0.90 | DYRK1A (0.64) | DYRK1ACLK2CLK3WNT1PIM1 | |
| SCHEMBL17588497 | 0.89 | DYRK1A (0.71) | DYRK1ACLK2CLK3WNT1GSK3B | |
| SCHEMBL17586967 | 0.89 | DYRK1A (0.71) | DYRK1ACLK2CLK3WNT1GSK3B | |
| SCHEMBL17588503 | 0.89 | DYRK1A (0.58) | DYRK1ACLK2CLK3WNT1GSK3B | |
| SCHEMBL18450707 | 0.88 | CLK2 (0.84) | DYRK1ACLK2CLK3PIM1 | |
| SCHEMBL17588501 | 0.87 | DYRK1A (0.71) | DYRK1ACLK2CLK3WNT1GSK3B | |
| SCHEMBL17586965 | 0.87 | WNT1 (0.69) | DYRK1ACLK2CLK3WNT1GSK3B | |
| SCHEMBL17583351 | 0.87 | WNT1 (0.71) | DYRK1ACLK2CLK3WNT1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081631-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-09-25 | — | — | US | claimed |
| US-20180215753-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-02 | — | — | US | claimed |
| US-9828372-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-11-28 | — | — | US | claimed |
| US-20170260179-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2017-09-14 | — | — | US | claimed |
| US-9475807-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | claimed |
| WO-2016040182-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2016-03-17 | — | — | WO | claimed |
| US-9828372-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828372-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170260179-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2017-09-14 | — | — | US | disclosed |
| US-20170260179-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2017-09-14 | — | — | US | disclosed |
| US-9475807-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475807-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160075701-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215753-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 735/4885CLK2 803/4885CLK3 655/4885 |
| US-20160075701-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 735/4885CLK2 803/4885CLK3 655/4885 |
| US-10081631-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | DYRK1A 735/4885CLK2 803/4885CLK3 655/4885 |
| US-20170260179-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 735/4885CLK2 803/4885CLK3 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.